Aug. 19 at 9:50 AM
$SCNX [RSS] The Company has until 10/12 to re-gain compliance with Nasdaq minimum Bid requirement. If the stock surges over
$1.0 in the interim for the requisite (10d) trading period, investors here will have all 2X their money and SCNX compliance re-instated. If/where the stock continues to trade here, the Company will announce an RSS, likely 15:1 (IMO) that will place the stock price above the
$5.0 penny stock threshold for broader institutional investment, while reducing the float to 2.1M approximately. Either situation (IMO) provides a material benefit to those invested at/around these levels. Arbli is scaling into the established network infrastructure at 97% GM, Rezenopy just launched into commercialization with the same infrastructure and larger addressable market - the Company has near-term liquidity with expectations of profitability by 2027. IP secured on both until 2041. Revenue scaling on both drugs, comparable GM provides the Company a good opportunity to that end.
